AUA 2024: Disrupting the Field of Urology
Speakers at the 2024 American Urological Association (AUA) annual meeting highlighted the innovations and advancements that are pushing the field of urology forward.
Related Articles
Atezolizumab Combo Results Shows Promising Option in EGFR-Mutated NSCLC
Atezolizumab combination therapy elicited better responses in patients with PD-L1 expression of 1% or more with EGFR-mutant NSCLC.
Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer
Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.
340B Program Does Not Increase Access to Targeted Therapy for Prostate Cancer
Researchers found that prostate cancer patients with greater socioeconomic disadvantages were less likely to receive targeted therapy, and participation in the 340B program did not…
How to treat older patients with follicular lymphoma in the first‑line setting
During the Lymphoma Hub Steering Committee meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, chaired a discussion on, How to treat older…
New Horizons in HSCT-TMA: Expert Perspectives and Pearls for Practice
This live educational event is intended for learners to be better able to understand the dynamic data evaluating diagnostic and care strategies for hematopoi…
Blood Pressure Fluctuations Linked to Cognitive Decline in Older Adults
A new study highlights the link between visit-to-visit blood pressure variability (BPV) and cognitive decline in older adults. Read on!
NXP800 activates the unfolded protein response, altering AR and E2F function to impact castration-resistant prostate cancer growth
Abstract. Purpose: Advanced prostate cancer (PCa) is invariably fatal with the androgen receptor (AR) being a major therapeutic target. AR signaling inhibitors have improved overall…
Belantamab mafodotin combination therapies in early RRMM
During the Multiple Myeloma Hub Steering Committee Meeting in November 2024, key opinion leaders met to discuss belantamab mafodotin combination therapies in early RRMM, with…
Home | AML Hub
Online resource for healthcare professionals, providing information, news & support relating to AML
Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL
Venetoclax-based treatment was associated with poorer outcomes CLL previously treated with a BTK inhibitor and naive to chemotherapy.